[{"id":"dde197cc-e99a-4873-8dba-a63667fc0334","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939283","created_at":"2025-06-28T16:10:57.563Z","updated_at":"2025-06-28T16:10:57.563Z","phase":"Phase 1/2","brief_title":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","source_id_and_acronym":"NCT06939283","lead_sponsor":"Werewolf Therapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WTX-330"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-04-22"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"11ff1fb4-2409-49a8-a992-90035263ebad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05361798","created_at":"2022-05-05T16:54:02.895Z","updated_at":"2025-02-25T13:40:59.644Z","phase":"Phase 2","brief_title":"T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05361798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"4cfc5715-dc42-47d6-8b29-f4162141b070","acronym":"20-C-0012","url":"https://clinicaltrials.gov/study/NCT04235777","created_at":"2021-01-29T07:20:15.829Z","updated_at":"2025-02-25T13:40:02.108Z","phase":"Phase 1","brief_title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","source_id_and_acronym":"NCT04235777 - 20-C-0012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-21"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"428cac7f-133f-43b4-8121-71893e06b7fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02498912","created_at":"2021-01-18T12:03:05.635Z","updated_at":"2025-02-25T14:35:42.787Z","phase":"Phase 1","brief_title":"Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors","source_id_and_acronym":"NCT02498912","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" MUC16 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • JCAR020"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-31"},{"id":"7258fe47-fdbb-4505-b15b-20957550273b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04303117","created_at":"2021-01-18T20:52:07.511Z","updated_at":"2024-07-02T16:34:26.828Z","phase":"Phase 1/2","brief_title":"NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma","source_id_and_acronym":"NCT04303117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-12"},{"id":"a5c7185c-9670-454c-8ccc-75c5b9dce3b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05684965","created_at":"2023-01-13T14:59:18.253Z","updated_at":"2024-07-02T16:35:15.101Z","phase":"Phase 1","brief_title":"XTX301 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05684965","lead_sponsor":"Xilio Development, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e efarindodekin alfa (XTX301)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-03-12"},{"id":"e9a2422f-d4f9-4a61-a157-fe8158579752","acronym":"","url":"https://clinicaltrials.gov/study/NCT05223816","created_at":"2022-02-05T18:29:35.392Z","updated_at":"2024-07-02T16:35:15.881Z","phase":"Phase 2","brief_title":"An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05223816","lead_sponsor":"Virogin Biotech Canada Ltd","biomarkers":" MSI • IDH1","pipe":" | ","alterations":" MSI-H/dMMR • IDH1 mutation","tags":["MSI • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-07"},{"id":"4e8d1c5a-aa92-47e5-9dde-7cd5c8707088","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756556","created_at":"2023-03-06T15:01:55.600Z","updated_at":"2024-07-02T16:35:21.279Z","phase":"Phase 2","brief_title":"T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma","source_id_and_acronym":"NCT05756556","lead_sponsor":"ImmVira Pharma Co. Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • T3011"],"overall_status":"Suspended","enrollment":" Enrollment 68","initiation":"Initiation: 06/30/2024","start_date":" 06/30/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-01"},{"id":"cdf035f3-57bf-43f0-9cb5-ab0631b1c1bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04756505","created_at":"2021-02-16T12:53:52.608Z","updated_at":"2024-07-02T16:35:25.096Z","phase":"Phase 1","brief_title":"Immunotherapy (NHS-IL12 \u0026 Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial","source_id_and_acronym":"NCT04756505","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/07/2021","start_date":" 03/07/2021","primary_txt":" Primary completion: 02/16/2022","primary_completion_date":" 02/16/2022","study_txt":" Completion: 02/16/2022","study_completion_date":" 02/16/2022","last_update_posted":"2023-12-27"},{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"c7e9b9c9-d4ce-4d93-91cb-690df0a318f7","acronym":"Delivir","url":"https://clinicaltrials.gov/study/NCT05788926","created_at":"2023-03-29T14:03:17.793Z","updated_at":"2024-07-02T16:35:32.334Z","phase":"Phase 1","brief_title":"A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)","source_id_and_acronym":"NCT05788926 - Delivir","lead_sponsor":"Transgene","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12","tags":["EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TG6050"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-10-20"},{"id":"b8562e47-8360-4e3a-9a00-3cb4c54257a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04370587","created_at":"2021-01-18T21:07:04.711Z","updated_at":"2024-07-02T16:35:38.768Z","phase":"Phase 1/2","brief_title":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04370587","lead_sponsor":"ImmVira Pharma Co. Ltd","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • T3011"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2023-08-29"},{"id":"5f5b7d90-82b7-4d29-a76d-1af846240ca3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008925","created_at":"2023-08-24T16:11:24.123Z","updated_at":"2024-07-02T16:35:39.126Z","phase":"Phase 1/2","brief_title":"Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer","source_id_and_acronym":"NCT06008925","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • CD8 • IL6 • NCAM1","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • IL6 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-08-24"},{"id":"80321407-2116-4248-84f6-3c84566bd252","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05902520","created_at":"2023-06-15T18:08:41.365Z","updated_at":"2024-07-02T16:35:42.423Z","phase":"Phase 1","brief_title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","source_id_and_acronym":"NCT05902520 - ACT","lead_sponsor":"AgonOx, Inc.","biomarkers":" BRAF • CD8","pipe":"","alterations":" ","tags":["BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AGX-148"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/19/2023","start_date":" 06/19/2023","primary_txt":" Primary completion: 05/19/2025","primary_completion_date":" 05/19/2025","study_txt":" Completion: 05/19/2026","study_completion_date":" 05/19/2026","last_update_posted":"2023-07-20"},{"id":"55ee843e-9dcb-4c92-8779-4c34cdfe315c","acronym":"KEYNOTE-890","url":"https://clinicaltrials.gov/study/NCT03567720","created_at":"2021-01-18T17:33:29.655Z","updated_at":"2025-02-25T16:08:03.661Z","phase":"Phase 2","brief_title":"Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC","source_id_and_acronym":"NCT03567720 - KEYNOTE-890","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" HER-2 • PD-L1 • ER","pipe":" | ","alterations":" PD-L1 negative","tags":["HER-2 • PD-L1 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • Tavo (tavokinogene telsaplasmid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-06-01"},{"id":"7661b4bf-26e4-407b-903a-7f38f8d7d0c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01502293","created_at":"2021-01-18T06:18:16.026Z","updated_at":"2024-07-02T16:35:47.973Z","phase":"Phase 2","brief_title":"Trial of pIL-12 Electroporation Malignant Melanoma","source_id_and_acronym":"NCT01502293","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tavo (tavokinogene telsaplasmid)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 02/14/2012","start_date":" 02/14/2012","primary_txt":" Primary completion: 03/21/2016","primary_completion_date":" 03/21/2016","study_txt":" Completion: 03/21/2016","study_completion_date":" 03/21/2016","last_update_posted":"2023-05-15"},{"id":"f0d43c41-1ece-4881-b43d-54ff7877742b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02531425","created_at":"2021-01-18T12:14:28.897Z","updated_at":"2024-07-02T16:35:48.002Z","phase":"Phase 1","brief_title":"Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC","source_id_and_acronym":"NCT02531425","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tavo (tavokinogene telsaplasmid)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2023-05-15"},{"id":"86c833c5-1bd1-4456-a4f8-3b0c16874085","acronym":"KEYNOTE 695","url":"https://clinicaltrials.gov/study/NCT03132675","created_at":"2021-01-18T15:26:06.079Z","updated_at":"2025-02-25T16:06:08.061Z","phase":"Phase 2","brief_title":"Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment","source_id_and_acronym":"NCT03132675 - KEYNOTE 695","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tavo (tavokinogene telsaplasmid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 143","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-03-27"},{"id":"d2fb6681-a16d-488c-b535-67b0e2be61b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05162118","created_at":"2021-12-17T17:31:15.748Z","updated_at":"2024-07-02T16:36:15.755Z","phase":"Phase 1/2","brief_title":"Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05162118","lead_sponsor":"Zhejiang University","biomarkers":" CD8 • PD-1 • IFNG • IL6 • TNFA • CD4 • NCAM1 • CA 19-9","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • TNFA • CD4 • NCAM1 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/08/2022","start_date":" 03/08/2022","primary_txt":" Primary completion: 03/22/2025","primary_completion_date":" 03/22/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2022-03-09"},{"id":"97e099ff-5286-4e2a-86a3-91ea5e73a0b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439085","created_at":"2021-01-29T07:16:58.643Z","updated_at":"2024-07-02T16:36:17.195Z","phase":"Phase 2","brief_title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","source_id_and_acronym":"NCT03439085","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • rocakinogene sifuplasmid (INO-9012) • INO-3112"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-14"},{"id":"b13de875-5cde-4e79-9e19-8d2093b80aca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01417546","created_at":"2021-01-29T07:02:13.424Z","updated_at":"2024-07-02T16:36:22.839Z","phase":"Phase 1","brief_title":"NHS-IL12 for Solid Tumors","source_id_and_acronym":"NCT01417546","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDS01ADC"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 12/12/2011","start_date":" 12/12/2011","primary_txt":" Primary completion: 06/02/2021","primary_completion_date":" 06/02/2021","study_txt":" Completion: 10/14/2021","study_completion_date":" 10/14/2021","last_update_posted":"2021-10-18"},{"id":"9cbb0ca0-237d-473a-96a5-93ed04df6129","acronym":"","url":"https://clinicaltrials.gov/study/NCT03679754","created_at":"2021-07-05T17:17:13.012Z","updated_at":"2024-07-02T16:36:24.160Z","phase":"Phase 1","brief_title":"Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102","source_id_and_acronym":"NCT03679754","lead_sponsor":"Alaunos Therapeutics","biomarkers":" CD8 • IFNG • CD4","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ad-RTS-hIL-12 • veledimex (INXN-1001)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/05/2018","start_date":" 09/05/2018","primary_txt":" Primary completion: 04/02/2019","primary_completion_date":" 04/02/2019","study_txt":" Completion: 01/19/2021","study_completion_date":" 01/19/2021","last_update_posted":"2021-09-22"}]